1. 104. Process development and cGMP manufacture of a targeted secretion inhibitor: a novel botulinum neurotoxin–based biotherapeutic platform. (January 2015) Authors: Hooker, Andy; Splevins, Andrew; Horrocks, Peter Journal: Toxicon Issue: Volume 93(2015)Supplement Page Start: S32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AbobotulinumtoxinA, onabotulinumtoxinA, and incobotulinumtoxinA neurotoxin content and activity: potential implications for duration of efficacy in patients. (December 2018) Authors: Field, Malgorzata; Splevins, Andrew; van der Schans, Marcel; Langenberg, Jan; Noort, Daan; Picaut, Philippe; Foster, Keith Journal: Toxicon Issue: Volume 156(2018)Supplement 1 Page Start: S33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. An evaluation of the cGMP manufacturing process economics and high-throughput characterization of targeted secretion inhibitors. (25th December 2016) Authors: Hooker, Andy; Splevins, Andrew; Horrocks, Peter; Dalby, Paul; Farid, Suzanne Journal: Toxicon Issue: Volume 123(2016) Supplement Page Start: S39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. An innovative solution to the unique challenges in manufacturing recombinant botulinum neurotoxins. (25th December 2016) Authors: Lovelock, Laura; Kwan, Daniel; Moore, Kevin; Splevins, Andrew; Marks, Phillip; Hooker, Andy; Horrocks, Peter Journal: Toxicon Issue: Volume 123(2016) Supplement Page Start: S56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Comparative botulinum neurotoxin type-A activity in the endopep assay—Formulation effects. (December 2018) Authors: Splevins, Andrew; van der Schans, Marcel; Langenberg, Jan; Noort, Daan; Foster, Keith Journal: Toxicon Issue: Volume 156(2018)Supplement 1 Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. HPLC analysis of recombinant botulinum neurotoxins: Expanding the analytic toolbox. (25th December 2016) Authors: Field, Malgorzata; Cummins, James; Mir, Imran; Splevins, Andrew; Hooker, Andy Journal: Toxicon Issue: Volume 123(2016) Supplement Page Start: S28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Informed manufacturing process development of a recombinant botulinum neurotoxin through the use of a sensitive and reproducible sandwich elisa. (25th December 2016) Authors: Splevins, Andrew; Field, Malgorzata; Mir, Imran; Hooker, Andy Journal: Toxicon Issue: Volume 123(2016) Page Start: S78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Quantity of prabotulinumtoxinA in 100-U vials. (January 2021) Authors: Allcock, David; Splevins, Andrew; Baig, Hamzah; Higazi, Daniel Journal: Toxicon Issue: Volume 190(2021)supplement 1 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗